{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T04:48:07Z","timestamp":1760244487400,"version":"build-2065373602"},"reference-count":33,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2022,11,26]],"date-time":"2022-11-26T00:00:00Z","timestamp":1669420800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Our primary aim was to estimate the magnitude of stage I endometrial cancer (EC) survivors that could benefit from hormonal therapy (HT). Our secondary aims were to assess EC incidence in women below 50 and below 60 over the years, and analyze the overall survival and any influencing factors. We analyzed the endometrioid EC data from the Surveillance, Epidemiology, and End Results (SEER) program according to women\u2019s age, tumor stage, and grade. We analyzed the proportions of EC survivors below 50 and below 60 years of age and stratified those age groups by race. For age distribution and survival analysis SEER, 18 registries\u2019 research data (2000\u20132018) were analyzed. We analyzed the SEER 12 registries\u2019 research data (1992\u20132019) for incidence time trends. Our investigation found a 14% and 40% cumulative prevalence of stage I EC that occurs in women below 50 or 60 years, respectively. EC\u2019s prevalence has progressively risen in recent decades, but cancer-specific mortality remains low. The increasing number of women affected by EC in premenopause or early postmenopause face an 18 years-survival rate of 96.86% and 95.73%, respectively. A significant proportion of low-grade EC survivors can potentially benefit from HT treatment, and this requires awareness of other aspects of their health or quality of life, in addition to cancer treatments.<\/jats:p>","DOI":"10.3390\/curroncol29120721","type":"journal-article","created":{"date-parts":[[2022,11,28]],"date-time":"2022-11-28T08:43:03Z","timestamp":1669624983000},"page":"9215-9223","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Quantification of Women Who Could Benefit from Hormone Therapy after Endometrial Cancer Treatment: An Analysis of SEER Data"],"prefix":"10.3390","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6429-1220","authenticated-orcid":false,"given":"Ambrogio P.","family":"Londero","sequence":"first","affiliation":[{"name":"Department of Neurology, Rehabilitation, Ophthalmology, Genetics, Maternal and Infant Health (DiNOGMI), University of Genoa, 16132 Genoa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8887-3823","authenticated-orcid":false,"given":"Anjeza","family":"Xholli","sequence":"additional","affiliation":[{"name":"Academic Unit of Obstetrics and Gynecology, IRCCS Ospedale San Martino, 16132 Genoa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1173-220X","authenticated-orcid":false,"given":"Serena","family":"Bertozzi","sequence":"additional","affiliation":[{"name":"Breast Unit, University Hospital of Udine, 33100 Udine, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9978-8130","authenticated-orcid":false,"given":"Maria","family":"Orsaria","sequence":"additional","affiliation":[{"name":"Institute of Pathologic Anatomy, DAME, University Hospital of Udine, 33100 Udine, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Paudice","sequence":"additional","affiliation":[{"name":"Anatomic Pathology Unit, Department of Surgical Sciences, and Integrated Diagnostics (DISC), University of Genoa, 16132 Genoa, Italy"},{"name":"Anatomic Pathology Unit, IRCCS Ospedale San Martino, 16132 Genoa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Mariuzzi","sequence":"additional","affiliation":[{"name":"Institute of Pathologic Anatomy, DAME, University Hospital of Udine, 33100 Udine, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2714-623X","authenticated-orcid":false,"given":"Angelo","family":"Cagnacci","sequence":"additional","affiliation":[{"name":"Department of Neurology, Rehabilitation, Ophthalmology, Genetics, Maternal and Infant Health (DiNOGMI), University of Genoa, 16132 Genoa, Italy"},{"name":"Academic Unit of Obstetrics and Gynecology, IRCCS Ospedale San Martino, 16132 Genoa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,11,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1080\/09513590.2022.2128105","article-title":"Hormone therapy in endometrial cancer survivors: Time for a change","volume":"38","author":"Cagnacci","year":"2022","journal-title":"Gynecol. Endocrinol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1007\/s12253-020-00817-z","article-title":"Prognostic Role of Kr\u00fcppel-Like Factors 5, 9, and 11 in Endometrial Endometrioid Cancer","volume":"26","author":"Viola","year":"2020","journal-title":"Pathol. Oncol. Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1016\/S0140-6736(22)00323-3","article-title":"Endometrial cancer","volume":"399","author":"Crosbie","year":"2022","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Londero, A., Parisi, N., Tassi, A., Bertozzi, S., and Cagnacci, A. (2021). Hormone Replacement Therapy in Endometrial Cancer Survivors: A Meta-Analysis. J. Clin. Med., 10.","DOI":"10.3390\/jcm10143165"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3109\/13697137.2015.1129166","article-title":"Fenton the IMS Writing Group 2016 IMS Recommendations on women\u2019s midlife health and menopause hormone therapy","volume":"19","author":"Baber","year":"2016","journal-title":"Climacteric"},{"key":"ref_7","first-page":"395","article-title":"Executive Committee of the Italian Society of Menopause (SIM) and of the Italian Society of Gynecology of the Third Age (SIGiTE) Recommendations on menopausal hormone replacement therapy","volume":"71","author":"Cagnacci","year":"2020","journal-title":"Minerva Ginecol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.maturitas.2022.04.008","article-title":"Menopause, wellbeing and health: A care pathway from the European Menopause and Andropause Society","volume":"163","author":"Lambrinoudaki","year":"2022","journal-title":"Maturitas"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.ygyno.2012.04.013","article-title":"Cardiovascular disease is the leading cause of death among endometrial cancer patients","volume":"126","author":"Ward","year":"2012","journal-title":"Gynecol. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1002\/ijc.30470","article-title":"High cardiovascular disease mortality after endometrial cancer diagnosis: Results from the Surveillance, Epidemiology, and End Results (SEER) Database","volume":"140","author":"Felix","year":"2016","journal-title":"Int. J. Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"102396","DOI":"10.1016\/j.ctrv.2022.102396","article-title":"GCIG-Consensus guideline for Long-term survivorship in gynecologic Cancer: A position paper from the gynecologic cancer Intergroup (GCIG) symptom benefit committee","volume":"107","author":"Woopen","year":"2022","journal-title":"Cancer Treat. Rev."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.ygyno.2017.12.025","article-title":"Long-term, adverse genitourinary outcomes among endometrial cancer survivors in a large, population-based cohort study","volume":"148","author":"Soisson","year":"2018","journal-title":"Gynecol. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s11764-015-0472-9","article-title":"Survivors of gynecologic malignancies: Impact of treatment on health and well-being","volume":"10","author":"Westin","year":"2015","journal-title":"J. Cancer Surviv."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ygyno.2019.08.007","article-title":"Recurrence, death, and secondary malignancy after ovarian conservation for young women with early-stage low-grade endometrial cancer","volume":"155","author":"Matsuo","year":"2019","journal-title":"Gynecol. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e94","DOI":"10.1097\/PAS.0000000000000749","article-title":"The Surveillance, Epidemiology, and End Results (SEER) Program and Pathology: Toward Strengthening the Critical Relationship","volume":"40","author":"Duggan","year":"2016","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_16","unstructured":"R Core Team (2022). R: A Language and Environment for Statistical Computing, R Foundation for Statistical Computing."},{"key":"ref_17","unstructured":"Lyubchich, V., and Gel, Y.R. (2022, August 11). Funtimes: Functions for Time Series Analysis; CRAN R-Project. Available online: https:\/\/cran.r-project.org\/web\/packages\/funtimes\/funtimes.pdf."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.ajog.2020.12.1213","article-title":"Ovarian conservation for young women with early-stage, low-grade endometrial cancer: A 2-step schema","volume":"224","author":"Matsuo","year":"2021","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"59940","DOI":"10.18632\/oncotarget.18404","article-title":"Ovarian preservation improves overall survival in young patients with early-stage endometrial cancer","volume":"8","author":"Jia","year":"2017","journal-title":"Oncotarget"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.ejca.2014.03.006","article-title":"Effects of hormone replacement therapy on the rate of recurrence in endometrial cancer survivors: A meta-analysis","volume":"50","author":"Shim","year":"2014","journal-title":"Eur. J. Cancer"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"126","DOI":"10.3747\/co.v15i3.204","article-title":"The Members of the Gynecology Cancer Disease Site Group Adjuvant Hormonal Therapy for Stage I Endometrial Cancer","volume":"15","author":"Gien","year":"2008","journal-title":"Curr. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Bartosch, C., Reis, S., Vieira, R., Pereira, A., Rodrigues, M., Jeronimo, C., and Lopes, J.M. (2015). Endometrial Endometrioid Carcinoma Metastases Show Decreased ER-Alpha and PR-A Expression Compared to Matched Primary Tumors. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0134969"},{"key":"ref_23","first-page":"555","article-title":"Estrogen replacement therapy in endometrial cancer patients: A matched control study","volume":"97","author":"Suriano","year":"2001","journal-title":"Obstet. Gynecol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.3892\/ol.2017.6640","article-title":"New use of microsatellite instability analysis in endometrial cancer","volume":"14","author":"Kunitomi","year":"2017","journal-title":"Oncol. Lett."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1055\/s-0033-1348896","article-title":"Racial and Ethnic Differences in the Pathogenesis and Clinical Manifestations of Uterine Leiomyoma","volume":"31","author":"Catherino","year":"2013","journal-title":"Semin. Reprod. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1530\/ERC-14-0250","article-title":"Variants of estrogen-related genes and breast cancer risk in European and African American women","volume":"21","author":"Quan","year":"2014","journal-title":"Endocr.-Relat. Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.ygyno.2017.12.021","article-title":"Clinical characteristics associated with racial disparities in endometrial cancer outcomes: A surveillance, epidemiology and end results analysis","volume":"148","author":"Sud","year":"2018","journal-title":"Gynecol. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ygyno.2017.12.009","article-title":"Racial disparities in molecular subtypes of endometrial cancer","volume":"149","author":"Dubil","year":"2018","journal-title":"Gynecol. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.ygyno.2017.10.037","article-title":"An NRG Oncology\/GOG study of molecular classification for risk prediction in endometrioid endometrial cancer","volume":"148","author":"Cosgrove","year":"2018","journal-title":"Gynecol. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s10549-013-2550-x","article-title":"Black race as a prognostic factor in triple-negative breast cancer patients treated with breast-conserving therapy: A large, single-institution retrospective analysis","volume":"139","author":"Perez","year":"2013","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s10549-012-2173-7","article-title":"Molecular characteristics and prognostic features of breast cancer in Nigerian compared with UK women","volume":"135","author":"Agboola","year":"2012","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1200\/JCO.2005.02.8464","article-title":"Randomized Double-Blind Trial of Estrogen Replacement Therapy Versus Placebo in Stage I or II Endometrial Cancer: A Gynecologic Oncology Group Study","volume":"24","author":"Barakat","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/cncr.23717","article-title":"Gynecologic Oncology Group Study Racial disparities in recurrence among patients with early-stage endometrial cancer: Is recurrence increased in black patients who receive estrogen replacement therapy?","volume":"113","author":"Maxwell","year":"2008","journal-title":"Cancer"}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/29\/12\/721\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:27:27Z","timestamp":1760146047000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/29\/12\/721"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,26]]},"references-count":33,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["curroncol29120721"],"URL":"https:\/\/doi.org\/10.3390\/curroncol29120721","relation":{},"ISSN":["1718-7729"],"issn-type":[{"type":"electronic","value":"1718-7729"}],"subject":[],"published":{"date-parts":[[2022,11,26]]}}}